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Cardiovascular disease remains a major cause of death for which current therapeutic regimens are limited.
Following myocardial injury, endogenous cardiac fibroblasts, which account for more than half of the cells in the
heart, proliferate and synthesize extracellular matrix, leading to fibrosis and heart failure. As terminally differentiated
cardiomyocytes have little regenerative capacity following injury, the development of cardiac regenerative therapy
is highly desired. Embryonic stem and induced pluripotent stem (iPS) cells are promising tools for regenerative
medicine. However, these stem cells demonstrate variable cardiac differentiation efficiency and tumorigenicity,
which must be resolved prior to clinical regenerative applications. Until the last decade, an established theory was
that cardiomyocytes could only be produced from fibroblasts through iPS cell generation. In 2010, we first reported
cardiac differentiation from fibroblasts by direct reprogramming, and we demonstrated that various cardiac
reprogramming pathways exist.
This review summarizes the latest trends in stem cell and regenerative research regarding iPS cells, a partial
reprogramming strategy, and direct cardiac reprogramming. We also examine the many recent advances in direct
cardiac reprogramming and explore the suitable utilization of these methods for regenerative medicine in the
cardiovascular field.
Keywords: Cardiomyocytes, Cardiac fibroblasts, Myocardial infarction, Transcription factors, microRNAs, Cardiac
regeneration, Induced cardiomyocytes, Direct reprogramming, iPS cellsBackground
According to “the top 10 causes of death” announced by
the World Health Organization (WHO), heart disease is
a leading cause of death in the world. Current thera-
peutic regimens for heart disease are limited. Heart dis-
ease, including heart failure and myocardial infarction, is
usually treated with medical therapy, mechanical device
implantation, and surgical intervention. When a patient
exhibits extremely poor cardiac function, a heart trans-
plant is typically required; however, donor shortage is a
major problem for heart transplantation (both in Japan
and throughout the world). Thus, cardiac regenerative
medicine is an attractive alternative therapy to heartCorrespondence: yamakawa@cpnet.med.keio.ac.jp
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stem (ES) cells have been used in the field of regenera-
tive medicine due to their self-replication competence
and cardiac differentiation ability; however, human ES
cells are accompanied by ethical and legal concerns, as
well as the threat of immunologic rejection. To solve
these problems, Yamanaka and colleagues developed in-
duced pluripotent stem (iPS) cells, which were created
by introducing four stem cell-specific transcription factors
(Oct3/4, Sox2, c-Myc, and Klf4; collectively, OSKM) into
human dermal fibroblasts [1]. However, if iPS cells are to
be used in clinical regenerative medicine applications
in the future, several issues must be resolved. For ex-
ample, these cells may demonstrate variable and low
cardiomyocyte differentiation efficiency, may require
a long time for cardiac maturation, and may show
tumorigenicity.le is distributed under the terms of the Creative Commons Attribution 4.0
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ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Yamakawa Inflammation and Regeneration  (2016) 36:23 Page 2 of 13The skeletal muscle master gene, MyoD, was discov-
ered in 1987 and spurred the search for a cardiomyo-
cyte master gene, which has yet to be identified.
However, the establishment of iPS cells suggested that
cardiac reprogramming could be achieved by concur-
rent introduction of several transcription factors, rather
than a single master gene, into fibroblasts. In fact, we first
reported that induced cardiomyocyte-like cells or induced
cardiomyocytes (iCMs) could be formed by transducing
fibroblasts with genes encoding the cardiac-specific tran-
scription factors, Gata4, Mef2c, and Tbx5 (collectively,
GMT) [2]. Prior to our work, an established theory was
that the reprogramming and subsequent differentiation of
fibroblasts into cardiomyocytes required an iPS cell inter-
mediate; however, our research introduced a new concept
in which a direct reprogramming pathway exists for the
production of cardiomyocytes from fibroblasts—one that
does not involve iPS cells.
Here, we summarize current knowledge about cardiac
reprogramming in vitro and in vivo. Furthermore, we
discuss future applications of cardiac reprogramming in
regenerative medicine.
Three pathways to generate new cardiomyocytes
The current methods of generating cardiomyocytes from
fibroblasts are categorized into three general pathways
(see Fig. 1):
(1)Full reprogramming of fibroblasts into iPS cells and
subsequent cardiac differentiationFig. 1 Three major pathways for deriving cardiomyocytes for myocardial re
(purple line), a partial reprogramming approach (orange line), and a direct re
can be transplanted into an infarcted or failing heart. Direct injection of tra
may be realized by the direct reprogramming approach, which would not
into the heart(2)Partial reprogramming of fibroblasts to cardiac
progenitor cells and subsequent differentiation
(3)Direct reprogramming of fibroblasts into
cardiomyocytes
The cardiomyocytes generated from any of these three
pathways can be transplanted into an infarcted or failing
heart. The direct reprogramming approach is particu-
larly attractive, as transcription factors involved in car-
diac reprogramming can be introduced directly into a
heart, bypassing the need for engrafting of iCMs. In this
section, we review preclinical and clinical data on these
cardiac regeneration strategies and summarize the ad-
vantages of each of these three strategies [3].




requirCurrently, the major strategy to generate
cardiomyocytes requires the full reprogramming of
fibroblasts into iPS cells and their subsequent
differentiation. This strategy requires complete
conversion of fibroblasts to undifferentiated cells
(e.g., iPS cells) and differentiation of iPS cells into
cardiomyocytes [4].
Mouse and human iPS cells were established by
Takahashi and Yamanaka in 2006 and 2007,
respectively [1, 4]. In both instances, iPS cells were
derived from fibroblasts by using retroviruses to
transduce the fibroblasts with genes encoding four
transcription factors (OSKM). iPS cells have broughtation. These strategies include a full reprogramming approach
amming approach (green line). Reprogrammed cardiomyocytes
tion factors involved in cardiac reprogramming into the heart
e engrafting of iCMs (derived from reprogrammed fibroblasts)
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[4]. Because they have a differentiation ability that is
similar to ES cells, iPS cells can be exposed to
cardiac differentiation protocols that were perfected
in ES cells. Following the initial establishment of
human iPS cells, functional analyses of iPS cell-
derived cardiomyocytes showed that they are em-
bryonic or immature cardiomyocytes rather than
adult-type cardiomyocytes [5, 6]. Cardiomyocytes
derived from human iPS cells have been used for
disease modeling [7], and many laboratories have
reported the analysis of models of various diseases
using iPS cells from fibroblasts derived from pa-
tients or animals with those diseases.
2) Partial reprogramming of fibroblasts to cardiac
progenitor cells and subsequent differentiation:
The second strategy to generate cardiomyocytes
requires the generation of partially reprogrammed
cells, including cardiac progenitor cells. These cells
can be generated during the process of iPS cell
generation by exposing fibroblasts to OSKM and can
be induced to differentiate into cardiomyocytes. Efe
et al. reported an equivalent partial reprogramming
method [8]. These researchers reported the successful
induction of cardiomyocytes from fibroblast cultures
transfected with OSKM, which were subsequently
treated with cardiomyocyte-inducing factors.
If Efe’s method induces partial reprogramming of
fibroblasts into cardiac progenitor cells, several
cardiomyocytes could be derived from a single
fibroblast during this procedure. However, whether
this strategy is applicable to human cells remains to
be determined.
Wang et al. demonstrated that Oct4 alone, together
with a small-molecule cocktail consisting of SB431542
(transforming growth factor beta (TGFβ) inhibitor),
CHIR99021 (glycogen synthase kinase 3 (GSK3)
inhibitor), Parnate (lysine-specific demethylase 1
(LSD1)/KDM1 (lysine(K)-specific demethylase1A)
inhibitor), and Forskolin (adenylyl cyclase activator)
(collectively, SCPF), is sufficient to “erase” the original
cell identity, thereby enabling cell conversion with
lineage-specific soluble signals [9]. In this case, bone
morphogenetic protein (BMP) 4 was added beginning
on day 6 after transduction to induce a cardiomyocyte
phenotype. By using this strategy, they observed con-
tracting clusters beginning on day 20 and generated
99 ± 17 beating clusters on day 30 after 10,000 mouse
embryonic fibroblasts (MEFs) were initially plated [9].
Very recently, Lalit et al. [10] and Zhang et al. [11]
reported two different strategies for reprogramming
adult mouse fibroblasts into highly expandable
cardiovascular progenitor cells [12]. They induced
mouse fibroblasts with combinations of transcriptionfactors and small molecules and succeeded in
expanding the cell populations they obtained in
chemically defined conditions.
Lalit et al. [10] found that mouse fibroblasts can be
infected with lentivirus harboring a doxycycline-
inducible transgene encoding five reprogramming
factors (Mesp1, Tbx5, Gata4, Nkx2.5, and Baf60c: col-
lectively, MTGNB), and that self-expanding cardiac
progenitor cells can be found with 6-bromoindirubin-
30-oxime (BIO; canonical Wnt activator) and
leukemia inhibitory factor (LIF; a JAK (Janus kinase)
/STAT (signal transducer and activator of transcrip-
tion) activator). These cells were called induced
cardiac progenitor cells and can be expanded over
1015-fold and differentiate into cardiomyocytes,
endothelial cells, and smooth muscle cells. Trans-
plantation of induced cardiac progenitor cells re-
sults in generation of all three of these lineages
in vivo and improves survival of mouse after
myocardial infarction [10].
Zhang et al. [11] utilized secondary MEFs, which
transiently overexpress the four Yamanaka factors
(OSKM) and showed that Yamanaka factor
expression plus the JAK inhibitor JI1 and BACS
(BMP4, activin A (the member of the transforming
growth factor beta (TGF-β)), CHIR99021, and
SU5402 (fibroblast growth factor receptor (FGFR)-
specific tyrosine kinase inhibitor)) reprograms mouse
fibroblasts into cardiac progenitor cells with a high
capacity for expansion. These cells were named
induced expandable cardiac progenitor cells, and
they differentiate into cardiomyocytes, endothelial
cells, and smooth muscle cells in vitro and after
transplantation into myocardial infarcted hearts [11].
3) Direct reprogramming of fibroblasts into
cardiomyocytes:
Recently, a third strategy was developed as a new
method to directly convert fibroblasts into another
cell type by introducing single or multiple
transcription factors. In 2010, Vierbuchen et al.
succeeded in generating neuronal-like or induced
neuronal cells by introducing three genes encoding
transcription factors (Ascl1, Brn2, and Mytl1)
necessary for neuronal differentiation into mouse
fibroblasts [13]. This was the first successful report
of direct reprogramming of fibroblasts into a specific
cell type (without an iPS cell step) using organ-
specific transcription factors.
Following the work of Vierbuchen and colleagues,
we reported that neonatal mouse cardiac fibroblasts
could be converted into cardiomyocyte-like cells or
iCMs following introduction of genes encoding
cardiac-specific transcription factors (Gata4, Mef2c,
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cells or induced hepatocytes from mouse fibroblasts
[14]. Direct reprogramming technology converts
terminally differentiated fibroblasts into another
organ cell type and does not require the formation
of iPS cells. In time, this strategy may provide a
safe and novel alternative to heart transplants. We
summarize the three strategies used to derive cardio-
myocytes from fibroblasts in Table 1.Direct cardiac reprogramming in vitro
Generation of mouse iCMs
Five years ago, we discovered that neonatal cardiac fibro-
blasts could be reprogrammed directly to form iCMs,
without going through an intermediate iPS cell phase (see
Table 2). Since then, multiple laboratories have reported
the generation of iCMs using various methods. As cell
sources for the generation of iCMs, we and others used
cardiac fibroblasts, tail-tip fibroblasts, or MEFs derived
from reporter mice that express a fluorescent protein
when a cardiac-specific promoter, α-myosin heavy
chain or cardiac troponin T (cTnT), is activated. To
overexpress reprogramming factors in fibroblasts, re-
searchers have used one of two techniques: (1) genes
encoding cardiac-specific transcription factors (Gata4,
Mef2c, Tbx5, Hand2, Myocd, etc.) were introduced into
cells with viral vectors (retroviruses, lentiviruses, ade-
noviruses, etc.); or (2) the lipofection method was used
to transfect cells with cardiac-specific microRNAs
(miRs). The reprogramming efficiency can be quantified
by counting the number of cells that express the cardiac
reporter or protein (by flow cytometry or fluorescence-
activated cell sorting) 1–3 weeks after introduction ofe 1 Three strategies to generate cardiomyocytes from fibroblas
trategies are shown






rties 1. Pluripotent cells
2. Bypass ethical and legal problems
(compared to ES cells)




tages Engraftment of ES cell-derived
cardiomyocytes is possible in large





vantages 1. Risk of teratoma formation
2. A long culture period (months) is
required to generate cardiomyocytes




2. Risk of tureprogramming factors into fibroblasts. As part of the
functional analysis, these cells were further evaluated for
spontaneous beating, calcium homeostasis, and action
potentials. Based on our epoch-making study, Song et al.
were able to produce functional iCMs (identified as
cTnT(+) cells) from adult cardiac fibroblasts and tail-tip
fibroblasts by adding a gene encoding a fourth transcrip-
tion factor—Hand2—to GMT (collectively GHMT) [15].
However, Chen et al. showed the difficulty in generating
functional cardiomyocytes through induction with GMT
and emphasized the need to examine the reprogramming
mechanisms and epigenetic changes induced with this
transcription factor cocktail [16].
Protze et al. introduced 120 combinations of factors
into MEFs using a pool of 10 transcription factors in an
attempt to induce cardiac differentiation and confirmed
cardiomyocyte properties in treated cells through gene
expression analyses. They showed that the 3F-Myocd
combination (Mef2c, Tbx5, and Myocd, in which Myocd
was substituted for Gata4) may result in cardiomyocytes
that are more differentiated than with other combina-
tions [17].
In addition, Jayawardena et al. introduced only the
microRNAs, miR-1, miR-133, miR-208, and miR-499, into
neonatal cardiac fibroblasts and succeeded in generating
iCMs, distinguishing this report from other research. As
microRNAs are not incorporated into host chromosomes
during transient expression, microRNA-mediated induc-
tion may be safer for human applications [18]. This re-
search also suggested that culture conditions are vital to
cardiomyocyte induction, as expression of α-myosin heavy
chain-cyan fluorescence protein (CFP) in transgenic mice
increased nearly tenfold when a JAK inhibitor was added












state (i.e., iPS cells, CPCs)
ture period (weeks) required
cardiomyocytes, compared
ediated cardiomyocytes
1. In vivo reprogramming
2. Takes 4 weeks to generate functional
cardiomyocytes
3. Lack of tumor formation
4. Generating only cardiomyocytes
n mechanism of OSKM-
CPC induction
mor formation
1. Immaturity of iCMs
2. Low efficiency of full reprogramming
into functional cardiomyocytes
3. iCMs are not proliferative
Table 2 Direct/partial reprogramming of mouse/rat fibroblasts to cardiomyocytes in vitro
Reprogramming factors Supplement agents Species Starting cell source Efficiency Comments References
Gata4, Mef2c, Tbx5 (GMT) Mouse Adult cardiac fibroblasts (CFs)
and tail-tip fibroblasts (TTFs)
20~30 % cTnT+ cells after
1 week
Beating after 4 weeks (CFs)
Using retrovirus and lentivirus
[2]
Oct4, Sox2, Klf4 (, c-Myc) JAK inhibitor I, BMP4 Mouse Mouse embryonic fibroblasts
(MEFs)
40 % cTnT(+) after 18 days Partial reprogramming
Beating after 18 days in cluster
Using secondary MEFs harboring doxycycline-
inducible transgenes encoding reprogramming
factors.
[8]
Oct4 ALK4/5/7 inhibitor, GSK3 inhibitor,
LSD/KDM1 inhibitor, BMP4
Mouse MEFs, TTTFs Make clusters Partial reprogramming
Beating after 20 days
Without any evidence of entrance into the
pluripotent state
Using doxycycline inducible-expression lentivirus-




BIO, LIF Mouse MEFs, CFs Passage over 20 times,
expand more than 1015-
fold
Partial reprogramming
Using a doxycycline-inducible lentivirus vector
[10]
Oct4, Sox2, Klf4, c-Myc
(OSKM)
JAK inhibitor (JI1), BACS (BMP4,
Activin A,CHIR99021, and SU5402)
Mouse MEFs, TTFs Expanded more than 1010-
fold
Partial reprogramming
Using secondary MEFs harboring doxycycline-
inducible transgenes encoding reprogramming
factors
[11]
Gata4, Mef2c, Tbx5 (GMT) Mouse CFs and TTFs 35 % cTnT+ cells Beating after 4~5 weeks
Using retrovirus
[15]
Gata4, Mef2c, Tbx5 (GMT) Mouse CFs and TTFs 35 % cTnT+ cells Beating after 4~5 weeks
Using lentivirus
[16]
Myocd, Mef2, Tbx5 (3F-
Myocd)










Mouse MEFs, CFs Almost 5 % the calcium
indicator GCaMP(+) cells
Using the induction of calcium oscillation for
screening
Utilizing an inducible-expression lentivirus-based




Mouse MEFs 2.4 % αMHC+ cells Using lentivirus [20]
GMT, miR-133 Mouse MEFs, CFs 40~50 % αMHC+ cells
(MEFs)










Mouse Adult CFs Tenfold increase in beating iCMs




TGFβ inhibitor Mouse MEFs, CFs 17 % the calcium indicator
GCaMP(+) cells
Beating approximately fivefold compared to 16)















Table 2 Direct/partial reprogramming of mouse/rat fibroblasts to cardiomyocytes in vitro (Continued)
Gata4, Mef2c, Tbx5, Hand2
(GHMT)
Akt1 Mouse MEFs, CFs, TTFs 50 % of reprogrammed
MEFs beating
Beating after 3 weeks
Using retrovirus
[25]
(−) CHIR99021, RepSox, Forskolin,
VPA, Parnate, TTNPB, DZnep
Mouse MEFs, TTFs Chemical reprogramming
Beating after 20–24 days
[26]
Gata4, Mef2c, Tbx5, Hand2
(GHMT), miR-1, miR-133
A83-01 (inhibitor of TGF-β1),
Y-27632 (inhibitor of ROCK)





FGF2, FGF10, VEGF, IWR-1 Mouse MEFs, CFs, TTFs 10–20 % αMHC(+) cells
after 1 week
1 % Beating after 4 weeks (GMT)
5~9 % Beating after 4 weeks (GHMT)
Using retrovirus
[28]
Mef2c, Tbx5 FGF2, FGF10, VEGF Mouse MEFs 3 % αMHC(+) cells after
1 week
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Hand2 to GMT if both factors were added to GMT. Using
a transgenic calcium fluorescent reporter driven by a
cardiomyocyte-specific gene promoter, they demonstrated
that infection with GMT, Hand2, and Nkx2-5 (collectively
HNGMT) results in the most efficient generation of func-
tional cardiomyocytes [19]. Christoforou et al. determined
that overexpression of Myocd and Srf (serum response
factor) transcription factors, alone or in conjunction with
Mesp1 and Smardcd3 (Baf60c), enhances the basal
cardiac-inducing effects of GMT. Through global gene ex-
pression analysis, they demonstrated the significantly
greater cardiac-inducing effects of Myocd and Srf com-
pared to GMTalone [20].
In 2014, we demonstrated that miR-133 overexpres-
sion paired with GMT generates sevenfold more beating
iCMs from MEFs compared to GMT treatment alone;
this treatment also shortened the duration required to
induce beating iCMs (from 30 to 10 days). Furthermore,
we found that miR-133-mediated Snai1 repression is
critical for cardiac reprogramming in adult mouse (and
human cardiac) fibroblasts, and that silencing fibroblast
signatures via miR-133/Snai1 is a key molecular roadblock
during cardiac reprogramming [21]. Importantly, this was
the first study to demonstrate a molecular mechanism
underlying cardiac reprogramming by defined factors.
Hirai et al. fused a transactivation domain from MyoD
to individual factors in the GHMTcocktail and found that
fusion of the Mef2c C-terminus with the MyoD transacti-
vation domain plus wild-type Gata4, Hand2, and Tbx5
accelerates cardiac reprogramming and generates larger
beating clusters from MEFs with a 15-fold greater effi-
ciency than GHMT without the fusion [22]. This result is
consistent with the observation that reprogramming re-
quires high levels of gene expression and activity to over-
come the high barrier of cellular stability that is inherently
present in adult somatic cells.
Wang et al. generated six polycistronic constructs to in-
clude all ordered combinations of Gata4, Mef2c, and Tbx5
with identical self-cleaving 2A sequences and showed dis-
tinct protein levels of the three transcription factors based
on the splicing order [23]. They further demonstrated that
relatively higher protein levels of Mef2c with modest levels
of Gata4 and Tbx5 lead to more efficient cardiac repro-
gramming, and an optimized MGT combination with
puromycin selection results in an over tenfold increase in
beating iCMs. This report convincingly showed that the
protein ratio of cardiac reprogramming factors could
greatly influence the efficiency and quality of iCMs.
Small molecules promote the reprogramming of mouse iCMs
Recently, multiple groups have shown that modification
of reprogramming factors can promote cardiac repro-
gramming. In particular, by stimulating or inhibiting thesignaling pathways involved in generation of cardiomyo-
cytes, they could improve cardiac reprogramming effi-
ciency. Cardiac reprogramming can also be affected by
cell culture conditions. These recent findings provide
new insights into the molecular mechanisms underlying
cardiac conversion of fibroblasts and will enhance efforts
to generate cardiomyocytes for clinical applications (see
Table 2).
Ifkovits et al. visualized the induction of calcium oscilla-
tions in reprogrammed cells with a transgenic calcium re-
porter, GCaMP5 (Ca2+ probe composed of a single GFP
5), driven by a cardiac-specific gene promoter. They found
that a combination of five cardiac transcription factors,
GMT, Hand2, and Nkx2.5 (GMTHN), more efficiently re-
programs MEFs. They also found that GCaMP5 helps
track the location of rare beating iCMs that represent fully
reprogrammed cells. With the same method, they found
that a small molecule inhibitor of TGF-β, SB431542,
increases reprogramming efficiency via GMTHN up to
nearly fivefold and generates more beating iCMs from
MEFs [24].
Zhou et al. discovered that Akt/protein kinase B
dramatically improves the efficiency of reprogramming
fibroblasts to iCMs by the cardiac transcription factors
GHMT. Approximately 50 % of reprogrammed MEFs
displayed spontaneous beating after 3 weeks of induction
by Akt plus GHMT. Insulin-like growth factor 1 and
phosphoinositol 3-kinase act upstream of Akt, whereas
the mitochondrial target of rapamycin complex 1 and
forkhead box O3 act downstream of Akt to influence
fibroblast-to-cardiomyocyte reprogramming [25].
Fu et al. reported generation of automatically beating
cardiomyocyte-like cells from mouse fibroblasts using
only chemical cocktails (CHIR99021, RepSox (inhibitor
of the TGFβ receptor-1/ALK5), Forskolin, VPA (valproic
acid; histone deacetylase inhibitor), Parnate, TTNPB
(Arotinoid acid; a synthetic stilbene analog of retinoic
acid (RA)), DZnep (3-Deazaneplanocin A hydrochloride;
histone methyltransferase EZH2 (enhancer of zeste
homolog 2) inhibitor)) [26]. These chemically induced
cardiomyocyte-like cells express cardiomyocyte-specific
markers and possess typical cardiac calcium transients
and electrophysiological features [26].
Zhao et al. reported that inhibition of the TGF-β1 or
Rho-associated kinase (ROCK) pathways converts embry-
onic fibroblasts into functional cardiomyocyte-like cells by
forced expression of GMT or GHMT, with an efficiency
of up to 60 %. Furthermore, inhibition of TGF-β1 or
ROCK signaling dramatically enhances full reprogram-
ming, with spontaneously beating cardiomyocytes emer-
ging in less than 2 weeks with GHMTalone [27].
In 2015, we demonstrated that a combination of
fibroblast growth factor (FGF) 2, FGF10, and vascular
endothelial growth factor (VEGF) promotes cardiac
Yamakawa Inflammation and Regeneration  (2016) 36:23 Page 8 of 13reprogramming in defined serum-free conditions, increas-
ing spontaneously beating iCMs by 100-fold compared
with other conventional serum-based conditions. Mechan-
istically, FGF2, FGF10, and VEGF activate multiple cardiac
transcriptional regulators and convert partially repro-
grammed cells into functional iCMs through the p38
mitogen-activated protein kinase and phosphoinositol 3-
kinase/AKT pathways. Moreover, our cocktail enables car-
diac reprogramming with only Mef2c and Tbx5 [28].
Generation of human iCMs
Three studies including ours applied the concept of
direct reprogramming to neonatal and adult human fi-
broblasts in 2013 [29–31] (see Table 3). Nam et al. re-
ported that a combination of genes encoding four
transcription factors (Gata4, Hand2, Tbx5, and Myocd)
and two muscle-specific microRNAs (miR-1 and miR-
133) can reprogram up to 20 % of human fibroblasts
into cTnT(+) cells (presumptive cardiomyocytes). Fur-
thermore, a subset of iCMs derived from human car-
diac fibroblasts demonstrated spontaneous beating after
11 weeks in culture [29]. Similarly, Fu et al. reported
that a mixture of genes encoding seven transcription
factors (Gata4, Mef2c, Tbx5, Mesp1, Myocd, Zfpm2,
Esrrg) can induce human cardiomyocyte gene expres-
sion in treated fibroblasts [30]. This work also demon-
strated that this mixture of reprogramming factors
generates epigenetically stable human iCMs, and that
TGF-β signaling improves the efficiency of human iCM
reprogramming [30]. Finally, we found that a combination
of genes encoding five transcription factors (Gata4, Mef2c,
Tbx5, Mesp1, and Myocd) can reprogram human fibro-
blasts into beating, cardiomyocyte-like cells with action
potentials when co-cultured with rat cardiomyocytes [31].
Islas et al. used two transcription factors (Mesp1 and Ets-
2) in activin A- and BMP2-treated cells to reprogram hu-
man dermal fibroblasts into cardiac progenitor-like cells,
which could then differentiate into cardiomyocyte-like
cells [32]. Despite these promising results, direct cardiac
reprogramming is less efficient in human cells compared
to mouse fibroblasts.
Muraoka et al. induced 2–8 % of α-actin(+)/cTnT(+)
cells with lentiviral transduction of Gata4, Mef2c, Tbx5,
Mesp1, and Myocd into human cardiac fibroblasts
(HCFs). Interestingly, by adding miR-133 to the repro-
gramming cocktail, they increased the efficiency of iCM
generation to 23–27 % [21].
In 2015, Li et al. reported that the combination of QQ-
reagent-modified Gata4, Hand2, Mef2c, and Tbx5 and
sevral cytokines (BMP4, activin A, FGF2, IWR1 (Wnt
pathway inhibitor)) reprogrammed human dermal fibro-
blasts (HDFs) into CPCs [33]. Like what Yamamakawa et
al. pointed out [28], the protein-transduction method can
directrely program with high efficiency. And finally, Caoet al. demonstrated that cardiomyocyte-like cells can be
generated by treating human fibroblasts with a combin-
ation of nine compounds (CHIR99021, A83-01 (Inhibitor
of TGF-beta type I receptor), BIX01294 (a histone methyl-
transferase (HMTase) inhibitor), SC1 (ERK 1 inhibitor),
Y27632 (ROCK inhibitor), OAC2 (Oct4-activating com-
pound 2), SU16F (inhibitor of platelet-derived growth
factor receptor-beta (PDGFR beta), and JNJ10198409 (in-
hibitor of platelet-derived growth factor receptor tyrosine
kinase (PDGF-RTK))). The chemically induced cardio-
myocyte-like cells uniformly contracted and resembled
human cardiomyocytes in their transcriptome, epigenetic,
and electrophysiological properties [34].
These protein reprogramming strategies have the
promising approaches for future regenerative medicine
both in vitro and in vivo. But the conversion of fibro-
blasts into human iCMs is not easy, compared with
mouse iCMs. Therefore, further research is essential to
identify optimal reprogramming factors (transcription fac-
tors, microRNAs, etc.) as well as culture conditions (small
molecules, cytokines, etc.) for improving reprogramming
efficiency and use in clinical applications [33, 34].
Direct cardiac reprogramming in vivo
The most exciting potential for cardiac transcription
factor-based reprogramming is the possibility of using this
technology in vivo. Injection of reprogramming factors
directly into the damaged heart may convert endogenous
cardiac fibroblasts, which represent >50 % of all cardiac
cells, into new functional cardiomyocytes. This in vivo re-
programming approach may have several advantages over
cell transplantation-based therapy. First, the process is
simple. Second, avoiding the induction of pluripotent cells
before cardiac differentiation would greatly lower the risk
of tumor formation. Third, direct injection of defined
factors obviates the need for cell transplantation, for
which long-term cell survival remains challenging [35–37]
(see Table 4).
For example, cardiac fibroblasts in an infarcted area of
a heart could be targeted for cardiogenic reprogram-
ming, resulting in the formation of new cardiomyocytes
in situ. In 2012, multiple groups including us demon-
strated the transdifferentiation of fibroblasts into cardio-
myocytes in vivo. Olson’s and Srivastava’s groups used
the Cre recombinase driven by fibroblast-specific pro-
moters to trace the cell fate of cardiac fibroblasts and
subsequent cardiomyocyte transdifferentiation.
Qian et al. used the periostin and fibroblast-specific
protein 1 (FSP-1) promoter Cre transgenic mice and
found that fibroblasts in infarcted hearts are converted
into cardiomyocyte-like cells by GMT retroviral gene
transfer; global function also restored in treated hearts
[38]. Following direct injection of GMT retroviruses
into infarcted mouse hearts, this work demonstrated
Table 3 Direct reprogramming of human fibroblasts to cardiomyocytes in vitro
Reprogramming factors Supplement agents Species Starting cell type Efficiency Comments References
Gata4, Hand2, Myocd, Tbx5,
miR-1, miR-133,
Human Human neonatal foreskin fibroblasts (HFF), adult
human cardiac fibroblasts (AHCFs) and and adult
human dermal fibroblasts (AHDFs)
~20 % cTnT(+) cells (HFFs)
13 % cTnT(+) cells (AHCFs)
9.5 % cTnT(+) cells (AHDFs)




Gata4, Mef2c, Tbx5, Mesp1,
Myocd, Zfp42/Rex1, ESRRG
Human Human cardiac fibroblasts (HCF) 35 % cTnT(+) cells Using retrovirus and
lentivirus
[30]
Gata4, Mef2c, Tbx5, Mesp1,
Myocd
Human Adult cardiac human fibroblasts (AHCFs) and adult
dermal fibroblasts (AHDFs)










Gata4, Mef2c, Tbx5, Mesp1,
Myocd, miR-133
Human Human cardiac fibroblasts (HCFs) 23~27 % cTNT(+) cells Using retrovirus [21]
Gata4, Mef2c, Tbx5, Hand2 Add supplement agents (BMP4,
activin A, FGF2, IWR1)
Human Adult human dermal human fibroblasts (AHDFs) Cardiac progenitor cells (?)
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[33]
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Table 4 Direct reprogramming of fibroblasts to cardiomyocytes in vivo
Reprogramming factors Gene transduction Species Disease model Comments References
Gata4, Mef2c, Tbx5 (GMT) Retrovirus Mouse Myocardial
infarction (MI)
Injected reprogrammed cells [2]




Mouse MI Improved survival after myocardial
infarction (MI)
Differentiate into cardiomyocytes,
smooth muscle cells, and endothelial
cells
[10]
Oct4, Sox2, Klf4, c-Myc
(OSKM)
(−) Using secondary MEFs harboring
doxycycline-inducible transgenes
encoding reprogramming factors
Mouse MI Improves heart function after MI
Reduce infract area Differentiate into
cardiomyocytes, smooth muscle cells,
and endothelial cells
[11]
Gata4, Hand2, Mef2c, Tbx5
(GHMT)
Retrovirus Mouse MI Injected virus
2.4~6.5 % (border zone) reduction of
50 % in scar zone
[15]
Gata4, Mef2c, Tbx5 (GMT) Lentivirus Mouse MI Injected reprogrammed cells [16]
Gata4, Mef2c, Tbx5 (GMT) Retrovirus Mouse MI Injected virus
Almost 35 % of iCMs in the border/infarct
area
Improvement 10 % in ejection fraction
[38]
Gata4, Mef2c, Tbx5 (GMT)
3F-2A system
Polycistronic vectors (retrovirus) Mouse MI Injected virus




microRNA Mouse MI Added JAK inhibitor
~1 % (border zone)
[18]
GMT and Vegf (GMT/VEGF) Lentivirus Rat MI Injected virus
Improvement in ejection fraction fourfold
greater in GMT/VEGF vs GMT only
[40]
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area or its border were newly generated iCMs derived
from resident cardiac fibroblasts. Furthermore, half of
these iCMs showed well-organized sarcomeric struc-
tures and exhibited functional characteristics of adult
ventricular cardiomyocytes, including cellular contrac-
tion, electrophysiological properties, and functional
coupling to other cardiac cells. These observations sug-
gested that in vivo reprogramming generates functional
iCMs more efficiently than in vitro reprogramming
[38]. In contrast to the work of Qian et al., Song et al.
added Hand2 to the GMT cocktail (creating a GHMT
cocktail) and utilized FSP-1 promoter Cre transgenic
and Tcf21-iCre knock-in mice for fibroblast lineage tra-
cing. They reported that GHMT retroviral injection
into mouse infarcted hearts converts endogenous car-
diac fibroblasts into functional cardiomyocyte-like cells
in vivo [15]. These researchers also demonstrated that
approximately 6 % of cardiomyocytes in the infarcted
area or its border were newly generated cardiomyocyte-
like cells with clear striations and functional properties
similar to those of endogenous ventricular cardiomyo-
cytes. Twelve weeks after myocardial infarction, Song
et al. also demonstrated that the scar zone of infarcted
hearts was reduced by 50 %, and the ejection fraction
was increased twofold in GHMT-treated mice com-
pared to controls [15].We generated a polycistronic retrovirus expressing
GMT. This polycistronic retrovirus, which expresses
GMT at near equimolar levels from the same promoter,
was generated using self-cleaving 2A peptides [39]. We
co-injected polycistronic GMT (3F2A) and reporter
genes (e.g., GFP) to determine cardiac induction from
non-myocytes. We found that gene transfer of this
polycistronic GMT retrovirus induces more mature
cardiomyocyte-like cells (as evidenced by sarcomeric
structures) than those generated by the injection of
three separate vectors.
Mathison et al. injected a mixture of GMT retroviruses
and VEGF into infarcted myocardium areas in rats. In-
farcted areas were reduced in rats treated with VEGF
compared to those only treated with GMT. This reduction
in the scar in the infarcted area may be due to VEGF-
mediated neovascularization or some other unknown
mechanisms [40].
Direct injection of lentiviruses containing four
microRNAs (miR-1, miR-133, miR-208, and miR-499)
into mouse infarcted hearts converts resident cardiac
fibroblasts into cardiomyocyte-like cells in vivo. After
injection of these microRNAs, Jayawardena et al. re-
ported that approximately 1 % of the infarcted area
contained new iCMs; however, this work did not report
on whether ejection fraction improved after microRNA
injection [18].
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delivery method, including chemically synthesized mole-
cules and microRNAs, may be a very attractive therapeutic
approach, because non-viral factors do not integrate into
the host chromosomes. Of note, these results suggest that
the abundant pool of endogenous cardiac fibroblasts could
be a cell source for new cardiomyocytes via direct repro-
gramming and that this new technology may improve
cardiac function and reduce scar size after myocardial
infarction. These studies clearly demonstrate that iCMs
reprogrammed in vivo are more mature than those repro-
grammed in vitro, suggesting that the effects of the in vivo
environment, such as mechanical stretch, local signals,
and the extracellular matrix, enhance the quality of iCMs
in the native heart.Conclusions
We reviewed the three different reprogramming strategies
that are being developed in the field of cardiac regenera-
tive medicine. Although all strategies (iPS cell approach,
partial reprogramming, and direct reprogramming) have
been utilized by many researchers, these strategies each
have several problems that must be overcome prior to
clinical application [41, 42].
The heart is composed of various groups of cells, in-
cluding blood vessel endothelial cells, smooth muscle
cells, nerve cells, and cardiac fibroblasts. Judging from
the absolute number of cells comprising the heart, car-
diomyocytes only account for approximately 30 % of
heart cells, whereas cardiac fibroblasts constitute ap-
proximately 50 % of this organ. When a large number
of cardiomyocytes die due to necrosis caused by myo-
cardial infarction, the number of cardiac fibroblasts in-
creases in the infarcted area. Heart rupture can be
prevented by replacing an infarcted area with fibrous
tissue; however, fibroblasts can result in low cardiac
function and a potentially fatal arrhythmic focus. Direct
reprogramming technology may provide an ideal treat-
ment that could bypass the formation of cardiac fibro-
blasts in an infarcted region, instead resulting in new
cardiomyocyte formation if certain genes are efficiently
introduced into cardiac tissue [43].
Today, almost all reports of successful direct cardiac
reprogramming have been generated with retroviruses
or lentiviruses (Tables 2, 3, and 4). These reports in-
volve integration in the host cell genome with an iden-
tified risk for insertional mutagenesis. To circumvent
such risks which are deemed incompatible with thera-
peutic prospects, significant progress has been made
with transgene-free reprogramming methods based on
other kinds of virus, microRNA [15], or the cocktail of
small molecules [26, 34] to achieve conversion into
cardiomyocytes.In the future, many scientists will examine the feasibility
of a novel reprogramming process based on transgene-
free methods using adenovirus, microRNAs, non-viral epi-
somal expression vectors, and protein transduction.
However, for direct reprogramming to be used in clin-
ical applications, the cardiac reprogramming efficiency
induced by this method must be optimized. The gener-
ation of sufficient numbers of fully reprogrammed cells
in vitro will also be valuable for drug toxicity studies and
drug screening. Currently, the reprogramming efficiency
of fibroblasts into mature cardiomyocytes is variable and
low. Although several reports have described direct re-
programming of human cardiac fibroblasts into cardio-
myocytes, further study is required for optimization.
On the other hand, current iCM technology is quite
efficient for in vivo reprogramming, and the iCM in vivo
reprogramming approach has several advantages over
cell-based transplantation therapy. Because reprogram-
ming factors are directly injected into the heart, no is-
sues arise concerning the homing, survival, or migration
of transplanted cells.
Future identification of small molecules or secreted
proteins that could replace each transcription factor, as
has been performed for iPS cell reprogramming, may
allow an alternative to gene therapy. We hope to utilize
regenerative medicine-based therapies to treat patients
with severe heart failure, potentially employing cardiac
muscle cells derived from iPS cells and iCMs.
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